Physician profile
Danielle Castillo
NPI 1457512667
$10,737.17
in general payments reported to CMS, 2019-2025
49 companies · $2,275 in 2025
The $2,275 reported for 2025 was more than what 79% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,229 · 2020: $557 · 2021: $1,018 · 2022: $1,577 · 2023: $1,752 · 2024: $2,328 · 2025: $2,275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,355.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,369.10 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,209.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $767.39 | 2019-2025 | Korlym |
| Radius Health, INC. | $630.08 | 2019-2025 | Tymlos |
| Amgen INC. | $629.61 | 2019-2025 | Evenity, Prolia, Tepezza |
| Xeris Pharmaceuticals, INC. | $521.45 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $478.35 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $464.68 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $399.92 | 2019-2025 | |
| Mannkind Corporation | $398.42 | 2020-2025 | Afrezza |
| Dexcom, INC. | $326.71 | 2019-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $319.46 | 2019-2024 | Omnipod |
| Abbvie INC. | $263.63 | 2023-2025 | Synthroid |
| Merck Sharp & Dohme LLC | $238.98 | 2019-2023 | Verquvo, Steglujan, Steglatro |
| Abbott Laboratories | $230.15 | 2020-2025 | Freestyle Libre 3, Proclaim, Eterna |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $209.12 | 2019-2024 | Lokelma |
| Medtronic, INC. | $197.47 | 2021-2025 | Minimed 780g |
| Pfizer INC. | $197.07 | 2021-2024 | |
| Ascendis Pharma Endocrinology INC | $175.80 | 2024-2025 | Yorvipath |
| Cequr Corporation | $158.77 | 2023-2025 | Cequr Simplicity |
| Lifescan, INC. | $146.43 | 2022-2023 | |
| Recordati_rare_diseases_inc. | $118.47 | 2022-2025 | Isturisa, Signifor Lar |
| Ibsa Pharma INC. | $114.11 | 2019-2025 | Licart, Tirosint, Tirosint |
| Ultragenyx Pharmaceutical INC. | $108.48 | 2021-2023 | |
| Amarin Pharma, INC. | $94.27 | 2020-2021 | |
| Beta Bionics, INC. | $88.41 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Kyowa Kirin, INC. | $87.53 | 2024-2025 | Crysvita |
| Horizon Therapeutics Plc | $80.99 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $71.31 | 2022-2024 | Unithroid |
| Alexion Pharmaceuticals, INC. | $66.43 | 2023-2024 | Strensiq |
| Tandem Diabetes Care, INC. | $61.42 | 2020-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Sequel Med Tech, LLC | $52.71 | 2025 | Twiist |
| Amphastar Pharmaceuticals, INC. | $49.07 | 2024 | Baqsimi |
| Endo USA, INC. | $46.13 | 2025 | Aveed |
| Eusa Pharma (US) LLC | $45.42 | 2022 | |
| Zealand Pharma US, INC. | $38.55 | 2021 | |
| Shire North American Group INC | $30.03 | 2019 | |
| Janssen Pharmaceuticals, INC | $29.79 | 2019 | |
| Vistapharm, INC. | $28.46 | 2021 | |
| Neurocrine Biosciences, INC. | $27.86 | 2025 | |
| Senseonics, Incorporated | $26.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $22.25 | 2025 | |
| Amryt Pharma Holdings LTD | $21.19 | 2023 | Mycapssa |
| Takeda Pharmaceuticals U.S.A., INC. | $20.43 | 2021 | |
| Acorda Therapeutics, INC | $18.41 | 2019 | |
| Acella Pharmaceuticals, LLC | $17.73 | 2025 | NP Thyroid 60 |
| Ucb, INC. | $15.74 | 2019 | |
| Tolmar, INC. | $13.19 | 2023 | |
| Medtronic Vascular, INC. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Castillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.